Aktie A196170 ALTEOGEN INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen ALTEOGEN Inc.

Aktien

A196170

KR7196170005

A196170

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 10.05.2024 		% 5 Tage % 1. Jan.
170.200 KRW +0,18 % Intraday Chart für ALTEOGEN Inc. -5,86 % +72,79 %
2023 Alteogen Inc. gibt bekannt, dass in der klinischen Studie mit Tergase kein Auftreten von ADA festgestellt wurde CI
2023 ALTEOGEN Inc. meldet Ergebnis für das erste Quartal zum 31. März 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA
ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
ALTEOGEN Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Alteogen And Sandoz Enter A Biosimilars Agreement Relating To Subcutaneous Products
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen's Hybrozyme Technology
ALTEOGEN Inc. Enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by its Hybrozyme Technology
Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
Alteogen Enters Into Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology
ALTEOGEN Inc. announced that it has received KRW 74.999925 billion in funding from SG Core Co., Ltd.
ALTEOGEN Inc. announced that it expects to receive KRW 74.999925 billion in funding from SG Core Co., Ltd.
ALTEOGEN Inc. announced that it has received KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation
ALTEOGEN Inc. announced that it expects to receive KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation
ALTEOGEN Inc.(KOSDAQ:A196170) added to FTSE All-World Index
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme Technology to Enable Subcutaneous Administration of Biologic Products
ALTEOGEN Inc. Presents the First-In-Human Data on Alt-P7, A Her2-Targeting Antibody-Drug Conjugate At ASCO 2020
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of its Hybrozyme™ Technology to Enable Subcutaneous Administration of Biologic Products
Alteogen Inc. Signs Licensing Agreement with Cristalia Produtos Quimicos Farmaceuticos Ltda
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
ALTEOGEN Inc. announced that it has received KRW 31.999718 billion in funding from KB Securities Co.,Ltd, Shinhan Investment Corp., Meritz Securities Co., Ltd., Korea Investment Holdings Co., Ltd., Kiwoom Securities Co., Ltd.
ALTEOGEN Inc. announced that it expects to receive KRW 31.999718 billion in funding from KB Securities Co.,Ltd, Shinhan Investment Corp., Meritz Securities Co., Ltd., Korea Investment Holdings Co., Ltd., Kiwoom Securities Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A196170 Aktie
  4. Nachrichten ALTEOGEN Inc.
  5. Andere Sprachen